key: cord-0774067-575ai8pi authors: Tiwari, Varsha; Kumar, Manish; Tiwari, Abhishek; Sahoo, Biswa Mohan; Singh, Sunil; Kumar, Suresh; Saharan, Renu title: Current trends in diagnosis and treatment strategies of COVID-19 infection date: 2021-10-02 journal: Environ Sci Pollut Res Int DOI: 10.1007/s11356-021-16715-z sha: fc05e3fe08b8f97b72105e6f173fef25e5763895 doc_id: 774067 cord_uid: 575ai8pi Coronaviruses are terrifically precise and adapted towards specialized respiratory epithelial cells, observed in organ culture and human volunteers both. This virus is found to possess an unpredictable anti-viral T-cell response which in turn results in T-cell activation and finally apoptosis, leading to cytokine storm and collapse of the whole immune system. The present review provides comprehensive information regarding SARS-CoV-2 infection, mutant strains, and the impact of SARS-COV-2 on vital organs, the pathophysiology of the disease, diagnostic tests available, and possible treatments. It also includes all the vaccines developed so far throughout the world to control this pandemic. Until now, 18 vaccines have been approved by the WHO and further 22 vaccines are in the third trial. This study also provides up-to-date information regarding the drugs repurposed in clinical trials and the recent status of allopathic drugs along with its result. Although vaccines are available, specific treatment is not available for the disease. Furthermore, the effect of vaccines on new variants is a new area of research at this time. Therefore, a preventive attitude is the best approach to fight against this virus. December 2019 has been documented as a historic month for the emergence of the coronavirus disease also called viral pneumonia in Wuhan, China. This outbreak has propounded to approx. 220 countries, possessing more than 180,906,466 confirmed cases with 3,919,082 confirmed deaths and recovered cases 165,531,010 all over the world until the 25 th of June 2021. The virus was primarily cautiously named 2019 novel coronavirus (2019-nCoV). Consequently, the International Committee of Taxonomy of Viruses coined the name SARS-CoV-2, and so the disease was named COVID-19 Chen et al. 2020) . This virus has been classified in genus, subgenus, and family: β-coronavirus, Sarbecovirus, and Coronaviridae respectively ( Fig. 1 ) Pottoo et al. 2021) . SARS-CoV-2, extremely contagious and lethal, became an immense global health issue. As per the gene sequence analysis, SARS-CoV-2 is pertinent with two SARS-like coronaviruses observed in bats (approx.88% resemblance) that possess rapid spreading characteristics all through the world. There are seven strains of coronavirus detected and identified which infect humans (HCoV), four of which are HCoV-229E, HCoV-NL63, HCoV-HKU1, and HCoV-OC43 that are common, seasonal, and liable to cause mild respiratory symptoms, whereas another two are zoonotic and virulent called MERS-CoV and SARS-CoV-1 and this SARS-CoV-2 possesses genetic similarity with SARS-CoV-1, both belonging to Sarbecovirus subgenus and β-coronavirus genus . Further study revealed that virus possesses envelope, +ve sense, single-strand of RNA linked with 30-kb genome (Arabi et al. 2020) . It possesses proofreading machinery in order to reduce the mistakes during replication, therefore the mutations. Research on SARS-CoV-2 revealed that it corresponds to Beta-coronavirus that possesses a characteristic genome structure as shown in Fig. 1 . This virus is the biggest known RNA virus that has a specialty in possessing a replication-transcription system (RTS). This also possesses 3′-5′ exo-ribonuclease (some RNAtransforming enzymes with approx. 148 proteins). The mechanism of infection in a human cell has been illustrated in Fig. 2 (Cevik et al. 2020) . Decoding of genome results into structural (four proteins, i.e., spike, membrane, envelope, and nucleocapsid) as well non-structural proteins (for replicase transcriptase proteins). It binds to ACE2 receptors through spike protein for cell attachment and entry. The disease shows flu-like symptoms such as fever, cough, loss of taste, diarrhea, pneumonia, renal, asthenia, cardiac symptoms, and skin rashes. Happy hypoxia is also observed in COVID-19-positive cases which is also responsible for the causalities. In some situations, the patient also feels acute traumatic stress disorder, depression, and some psychological disorders, and few cases commit suicide also due to it (Markham and Keam 2018) . The effect of SARS Cov-2 on various vital organs is shown in Fig. 3 . The coronavirus term implies a huge virus's family known since a long time ago. Before this pandemic, many coronaviruses are known to infect humans and cause mild respiratory illnesses such as cough and colds. This novel COVID-19 virus is not new to us but it is very rare that a virus jumps from animals/plants to humans and causes disease. This happens with the COVID-19 virus; therefore, it infects humans rapidly, due to its extreme contagious nature (Jena 2021; Jha et al. 2021; Jin et al. 2020; Shahab et al. 2021 . Variants known to date are compiled in Table 1 . It is well known that viruses are the link between living and non-living organisms as they do not contain any cells. Therefore, there are more chances of mutations in viruses during human infection as well as disease progressions as the simplest structure. Most of the mutations are harmful to the organisms but few may be beneficial too. As a result of mutations, these viruses may appear in a little bit different form and can cause the disease in an extreme contagious manner as shown in the case of the COVID-19 virus. D614G was found to be the first variant that has been observed near late January or early February 2019 and replaced the original strain somewhere in June 2020 which became dominant and spread throughout the world. The enhanced infectivity and transmission have been observed without a change in the severity of the disease. Cluster 5, another mutant, has been observed somewhere between August and September 2020 through Danish personnel infected by framed mink which later jumped to humans. As the name suggests, Cluster 5 is an aggregate of strains, observed in 12 persons until now, not found to spread extensively. SARS-CoV-2 VOC 202012/01 (mutant of interest) has been reported by UK personnel to the WHO (December 14, 2020) . This mutant possesses 23 nucleotide changes found to be not related phylogenetically to the SARS-CoV-2 virus, the main cause of coronavirus disease at that time. Due to the above substitutions, this strain was found to possess enhanced transmissibility without any change in disease severity (Ruan et al. 2020) . The variants that are known and the different mutants along with the site of mutations are summarized in Table 2 . Triple mutation in COVID-19 has also been observed in few parts of Delhi, West Bengal, and Maharashtra. Mutations at sites 452 and 484 have been reported individually; for example, in California, variants B.1.427 and B.1.429 have the L452R mutation. E484K has been seen in the variants reported from the UK, South Africa, and Brazil. Mutations at site P681 have also been seen in some lineages before as well as the mutation E484Q. The combination of all the three mutations reported here, L452R, E484Q, and P681R, suggests the virus emerging similar traits autonomously, continually adapting to its human hosts (Perrella et al. 2020; Del Rio et al. 2020 ). When a virus enters in body through the nose or mouth, it stays near the paranasal cavity and tries to make colonies, which results in headache and loss of smell and taste at the very first level. After 24-36 h, it invades the respiratory and gastrointestinal system and causes abdominal pain and loss of motion. The body defense system activates, and macrophages accumulate at the site and try to engulf the virus and send the messages in a form of IL-1, IL-6, and TNF to other body cells as well as neutrophils to be active against infection. By the examining IL-6 level, we can make an idea regarding the body's preparation against the virus. As the disease progresses, further neutrophils accumulate and try to kill the virus, but body cells will also be affected. At 5-6 days of the disease, chances of cytokine storm occur due to over responsiveness of the body. The virus attacks on type 2 Shahab et al. (2021) pneumocytes, which secrets some surfactants and helps in lung expansion during respiration. Another target for the virus is the liver and kidney. Macrophage activates the liver to produce a c-reactive protein which gives signals to other parts of the body to be overreactive against infection (Jain 2020) . These signals can also act on the liver to produce and release fibrinogen which when reacts with platelets forming unnecessary clots in the body which floats in the blood and can block any artery/vein that may result in pulmonary embolism, heart attack, and stroke. These blood clots can be examined by testing the level of d-driver. When an infection invades the heart cells, it releases HSCRP which causes damage to the cardiac muscle cells. Cytokines can activate the thermo regulators in the hypothalamus and result in fever. The liver function and cell damage can be checked by examining SGOT, SGPT, blood level. Cell damage can be checked through LDH level and a patient's life can be saved by taking therapy on time (Favalli et al. 2020) . Once SARS-CoV-2 enters the alveolus, it begins to infect type II alveolar cells and replicate. The infected type II alveolar cells release pro-inflammatory cytokines, which signal the immune system to respond. Patients may experience mild symptoms, such as cough, fever, and body aches. Macrophages release IL-1, IL-6, and TNF-I. IL-6, causing vasodilation and allowing more immune cells to travel to the alveolus. It also increases capillary permeability, causing plasma to leak into the interstitial space and the alveolus. Neutrophils release reactive oxygen species and proteinases, which destroy infected cells. These dead cells combine with the plasma to form a protein-rich fluid that accumulates within the alveolus, causing shortness of breath and pneumonia. Accumulation of fluid and dilution of surfactant lining of the alveolus cause alveolar collapse, which decreases gas exchange and can lead to hypoxemia and acute respiratory distress syndrome. If the immune system goes into overdrive, inflammation can spread throughout the circulatory system, leading to systemic inflammatory response syndrome, also known as a cytokine storm. This systemic inflammation can cause septic shock, where blood pressure drops dangerously low and organs can no longer be perfused, leading to multiorgan failure and death. As explained in the preceding sections, the SARS-Cov-2 virus has undergone numerous changes, resulting in more dangerous variants. In type 2 asthmatic individuals, COVID-19 infection becomes more severe. They also outline the treatment options and medications that can be utilized to address mild, moderate, and severe COVID-19 symptoms in asthmatic patients, preventing aggravation. The progressive results were highly contradictory, as severe cases of COVID-19 showed an increase in the levels of numerous cytokines that might exacerbate bronchial tract inflammation, exacerbating asthma attacks. Contrary to popular belief, certain data show that COVID-19 severity is reduced in type 2 asthmatic patients with elevated T-cells, since most COVID-19 positive individuals have a significant drop in T-cells. This helps to restore the balance of immunological responses, slowing the advancement of the disease (Ghosh et al. 2021) . Obesity stimulates the development of gene-induced hypoxia and adipogenesis in obese mice. Obesity increases the likelihood of developing immune-mediated and certain inflammatory-mediated illnesses, such as atherosclerosis and psoriasis, by dampening the immunological response to infectious pathogens, resulting in weakened post-infection effects. Furthermore, the obese host produces a unique milieu for disease development, characterized by low-grade inflammation that persists. To protect our bodies and reduce the danger of infectious illnesses, including COVID-19, it is recommended to maintain good eating habits by increasing the intake of diverse plant-based and low-fat meals . The virus appears to enter the CNS mainly via the angiotensin-converting enzyme-2 (ACE-2) receptor and nasal route through the olfactory bulb and cribriform plate and propagates through trans-synaptic signaling, and moves retrogradely into the CNS along the nerve fiber, according to evidence. Parkinsonism, Alzheimer's disease, meningitis, encephalopathy, anosmia, hyposmia, anxiety, sadness, psychiatric symptoms, seizures, stroke, and other problems have been linked to viral invasion of the CNS. As a consequence, even after the individual has cured from COVID-19, the COVID-19 CNS components should be checked on a regular basis to prevent long-term CNS issues (Nagu et al. 2020 ). Recently, two types of tests have been performed for the diagnosis: a. Molecular tests b. Antigen tests. Antibody test targets the antibodies that have been produced in patient's blood with response to viral infection but it can be detected in post-COVID-19 patients also (Shahab et al. 2021; Ojha et al. 2021; Shoaib et al. 2021) . Diagnostic tests are compiled in Table 3 and Fig. 4 . The repurposed drugs used in the management of SARS COV-2 infections (Pawelczyk and Zaprutko 2020; Parasher 2021; Saxena 2020; Gil et al. 2020 ) are listed and compiled in Table 4 . Different drugs along with the mechanism of action in the management of SARS COV-2 are shown in Fig. 5 . Chloroquine/hydroxychloroquine The mechanism of chloroquine and hydroxyl-chloroquine drugs involves the conversion of chloroquine to hydroxychloroquine which in turn inhibits several enzymes. Due to enzyme inhibition, viral entry is inhibited due to these weak bases because of pH dependency. The drug also inhibits glycosyl-transferases and post-translation modifications and also inhibits viral families. The mechanism of action is depicted in Fig.6 (Schrezenmeier and Dörne 2020). Favipiravir is an approved drug employed for severe influenza virus infection in China. It is available in an inactive form and gets converted into an active form by the action of enzymes into favipiravir ribo-furanosyl monophosphate (RMP) which further converts into the active form (favipiravir ribofuranosyl triphosphate) which in turn can block the replication of several RNA viruses currently in clinical trials in COVID-19 management. The mechanism of action has been presented in Fig. 7 (Sood et al. 2021 ). It is a broad-spectrum antiviral drug; adenosine analog that can determine pre-mature termination of viral RNA. It has been tested for Ebola virus infection and might be useful in the treatment of other RNA virus infections. It has been shown that the action against SARS COV-2 infection also, still, studies are going on and showed in Fig. 8 (Beigel et al. 2019; Wang et al. 2020a ). Monoclonal antibodies can be produced by immunizing the rats with antigens but sometimes failed to secrete antibodies. This can be further modified by mixing the myeloma cells with plasma cells from the spleen. Cell fusion results in hybridomas cells, which are transferred to hat medium and incubated. Hybridomas cells are further selected which produced antibodies known as monoclonal antibodies. These antibodies are found to be effective against COVID-19 and came in light when given to the ex-US president Donald Trump. The monoclonal antibody cocktail is a combination of two or more monoclonal antibodies which is administered to the patient as a single dose. These are found to exhibit activity by acting on the spike protein of the COVID-19 and do not allow it to enter into the human cell. Recently, Zydus claimed regarding the repurposing of "Virafin" (pegylated interferon alpha-2b) in COVID-19 treatment which was earlier used in the treatment of the hepatitis C virus. Recently, Virafin has been given limited emergency approval from DCGI, India (Science The Wire 2021). One more drug named "2-DG" has been developed by DRDO along with Dr. Reddy's Lab. Hyderabad has been granted emergency approval from DCGI, India as an adjunct therapy to overcome oxygen demand. This drug has been developed in the treatment of cancer as it possesses promising cytotoxic potential (Economic times. Indiatimes 2021). Currently, Canadian company Sanotize developed nitric oxide-based nasal spray, claimed to kill COVID-19 load inside the nose up to 99.99 %. Now, the company has filed for getting emergency approval in the UK and started its production in Israel (India today 2021). Vaccines are the hope for controlling this pandemic caused by the COVID-19 virus. Few vaccines have been approved by regulatory authorization whereas some of them are in the process. It should be very clear that no vaccine is 100% effective until now; still results will prove the efficacy and safety of the vaccines. Each and every person must follow the guidelines and hygienic conditions. Scientists all over the world are working at war level for the production of vaccines; until now, 79 vaccines are still in process and among them, 11 vaccines have been approved by regulatory authorities whereas 20 vaccines are still in phase III clinical trials (Li and De Clercq 2020; Li et al, 2020a; Zoomer 2021; Graham, 2020) Vaccines that have been approved by regulatory authorities until now are shown in Table 5 . The list of approved vaccines in phase trial 3 is compiled in Table 6 . Nano-technology possesses enormous potential in targeted drug delivery at the target site with minimum side effects, .Antivirals Baloxavir Antiviral active against influenza viruses Conflicting data regarding possible in vitro antiviral activity against SARS-CoV-2 Although investigated as a potential treatment during the early stages of the COVID-19 pandemic, 1, 6, 7 in vitro antiviral activity against SARS-CoV-2 was not confirmed and there are no data to support the use of baloxavir in the treatment of COVID-19. Methyl-prednisolone These corticosteroids may be beneficial in severely/critically infected patients but they should be taken precautiously due to side effects. A widely used glucocorticoid called methyl-prednisolone is being studied for safety and effectiveness in the treatment of novel coronavirus pneumonia in a number of hospitals in the Hubei province of China. The role of commercially available immune globulin (non-SARS-CoV-2-specific IGIV) and investigational anti-SARS-CoV-2 hyperimmune globulin (anti-SARS-CoV-2 hIGIV) in the treatment of COVID-19 is unclear. Jawhara (2020) There is a lack of published information and guidance on the optimal administration of aerosolized drugs in the treatment of patients with COVID-19. The safe and effective delivery of aerosol therapy to such patients may require modifications in dosage, frequency, and Simonds et al. (2010) especially in the anticancer domain. This technology has been extensively utilized in the development of vaccines against the COVID-19 virus. Viruses can be categorized as nanoparticles, which work at similar measures as other nanomaterials. There has been a lot of research performed as well as ongoing to mimic the nanoparticle-like virus behavior for designing the target drug release as well as gene delivery regimens (Singh et al. 2017 ). Therefore, nanotechnology may offer great value in the present ongoing pandemic via various ways such as viral Being an anticancer drug also possesses anti-inflammatory potential via inhibiting NLRP 3 inflammasome leads to inhibit the cytokine production or cytokine storm is the major cause of inflammation in COVID-19 infection. Apart from it possesses a pleotropic mechanism, not possessing immunosuppressive potential, cheap, and does not augment the infection risk. This drug may interfere with the SARS-CoV-2 RNA, may hamper both transcription and translation. It also increases the pH of endosomes/lysosomes results in protease inhibition and fusion with auto-phagosomes thus results in inhibition of viral release and enhance auto-phagolysosomes. Pineda et al. (2021) neutralization and detection, vaccine developments, and providing effective treatment (Florindo et al. 2020) . Nanoparticles possess similarity to coronavirus, excluding viral genome if nanoparticles enter the host cells renovate immunity against this type of infection. Due to similar size nanoparticles may bind to the COVID-19 virus and distort its structure along with IR treatment which further results in hampering the viral survival and reproducibility (Yang 2021) . Various nanoparticles such as gold and carbon quantum dots (CQDs) are excellent options for interacting with the virus as well as averting entry within the cells due to the large surface area as well as a broad range of functional groups. CQDs possess a diameter 10 nm approx. and good water Gold nanoparticles using extracts impart additional advantages such as being eco-friendly, non-toxic, cost-effective, and easily accessible. Research performed so far revealed that gold nanoparticles can be stabilized with few polymers (bio-compatible) that might act as antiviral agents against HIV 1, FMDB, diarrhea, dengue, H1N1, H3N2, and H5N1 virus (Medhi et al. 2020) . Silver, iron, mesoporous silica (Wang et al. 2017; Lara et al. 2010; Rojas et al. 2020; Rai et al. 2016 ) and organic particles such as Carbon nanotubes & Nanoparticles Graphene, Polymeric, Lipid-based, Dendrimers revolution in nanotechnology employing novel nanocarriers and magnetic nanoparticles (Comparetti et al 2018; Alidori et al. 2016; Mangum et al. 2006; Singh et al. 2019; Hennig et al. 2015; Figueroa et al. 2019; Pollock et al. 2010; Jain et al. 2011; Shah et al. 2017; Lembo et al. 2018; Li et al. 2005; Clayton et al. 2009; Itani et al. 2020; Williams & Corr 2013) have been documented in the treatment of Covid-19. The current strategies of nanoparticles used in the treatment of COVID-19 infection are shown in Table 7 . An epidemic of pneumonia that started in December 2019 (Wuhan-China) has been well known to be due to novel coronavirus, which has been named later as COVID-19. The virus is extremely contagious and results in pandemic situations due to the lack of any medicine for prophylaxis as well as treatment. Subsequently, searching the effective prophylactic and therapeutic strategies for the management of the disease is still continuing. Furthermore, the emergency requirement of drugs leads to the repurposing of drugs which has been mentioned in this article. We illustrated categorized response based on infection and contiguity stages of diseases among the human population. Despite the fact that until now no medicine system provides clinically proven treatment for COVID-19, continuous research is ongoing searching for the effective treatment for COVID-19( Fig. 10) (Silva et al. 2020; Sadlon et al. 2010; Rosa et al. 2020; Jin et al. 2020) . Moreover, vaccines, anti-viral drugs, and antibiotics possess the gold standard for the current preventive measures for different epidemic disorders until now. Furthermore, problems related to developing dispensing, side effects, storage conditions, mutations, and antibiotic-resistant microbes should also be taken into considerations. Novel approaches for communicable diseases are absolutely required and the WHO also mentioned that at the time of the Ebola outbreak in 2014. The expert committee stated that it's unethical to suggest unproven intercession with unknown efficiency as well as adverse effects as promising treatment/prophylaxis. It should be taken into consideration that it's not only COVID-19, but there are also other viruses as well as diseases for their vaccines, and clinically proven treatment is not available. Therefore, innovative research, as well as technique, is absolutely required for providing effective medication to society (Fig. 11) (Veronese et al. 2020; Reyes et al. 2020; Michael and Thompson 2020; Cox et al. 2021; Furuta et al. 2017; Cristian et al. 2020; Chaccour et al. 2021 ). Vaccine development takes an average of 10-15 years, and compressing it to just 15 months has its own set of drawbacks and issues. Combining stages to accelerate vaccine development necessitates testing on smaller groups. This is a major issue because, if the vaccine is made available to the general public, unexpected adverse effects may develop in bigger groups that were previously undetected in smaller groups. Furthermore, if all individuals with comorbidities are not properly addressed in the design of clinical trials, NPs have been observed to possess significant virucidal potential via amino alkylation of genome lads to arresting replication and viral inactivation. Mannose-loaded IONPs for dendritic delivery have been shown a significant increase in IL-6, TNF-α, and IFN-γ has been observed in dendritic cells in in-vitro analysis. Recent research showed that interaction between SARS-CoV-2 and hemoglobin results in denaturation of hemoglobin and thus dysregulates the iron mechanism which may lead to other complications. Rojas et al. (2020) d. Another nano-approach of mesoporous silica possesses integrate pore size, can accommodate molecules for codelivery. This character makes these an excellent platform for inactivating the entry as well as averting the viral replication of COVID-19 within the host cell. (1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenyl benzamide (ML336) complex have been established in order to enhance the antiviral circulation period and its biocompatibility. In vitro results showed dose-dependent viral inhibition whereas in vivo results revealed significant antiviral potential with no toxicity. Rai et al. unexpected adverse effects may be discovered in those groups once the vaccine is ready for general use. Vaccines would be examined for similar adverse effects in the broader population under post-marketing surveillance. It's uncertain how mRNA vaccines will be developed since in past researches. Nucleic acid-based vaccines like DNA and RNA have failed to generate viable vaccinations for human diseases in the past. Because lipid nanoparticles are temperature sensitive, scaling up production may be difficult. Pre-existing adenovirus immunity is a concern, particularly for vaccine candidates that utilize human adenoviruses, such as CanSino's Ad5 vaccine, since it may reduce the vaccine's immunological response (Sharma et al. 2020) . In order to meet pandemic demand, rapid large-scale vaccine production remains a challenge fraught with uncertainties. Because phase 3 trials need more than 30,000 individuals and are performed later in the study phase, there is a high chance that there will be fewer instances of COVID-19 at that time, requiring HCTs. Despite the fact that HCTs have been utilized in the past, they may pose a higher risk for COVID-19 due to a lack of understanding of the disease's genesis and the absence of a feasible treatment. As an alternative to HCTs, several vaccine candidates have taken advantage of transmission rate differences by starting phase 3 trials in countries with a higher SARS-CoV-2 infection rate to Research reported the use of iron oxide coated with silica for RNA extraction from the sample. Williams and Corr (2013) . Unique optical and electrical properties QD-linked RNA particularly against SARS-CoV N protein has been informed to possess high sensitivity for detection of restrained viral protein on intended chips. Marketed QD-605 possess emission maxima (605nm) to access an excellent detection limit of 0.1 pg/mL against SARS-CoV N through confocal laser scanning microscopy. Iannazzo D et al. The COVID-19 pandemic is still a global health issue that has impacted a vast number of people. From December 2019 onwards, most nations around the world have recorded a substantial number of COVID-19 cases. There are currently no effective vaccinations or medications available to prevent COVID-19 infection. To address these health issues, various research groups are working to determine the most effective treatment for COVID-19 by delivering FDA-approved antiviral medicines such as oseltamivir, ritonavir, remdesivir, ribavirin, and favipiravir, among others. Simultaneously, scientists are concentrating on the creation of several types of vaccinations that can prevent COVID-19 infection. According to the survey results, research will continue until acceptable drug candidates and vaccines are found based on pathological conditions, physiology, clinical symptoms, diagnosis, and public health emergencies. Keeping in view of this epidemic, we're still waiting for precise COVID-19 treatment and care. Although a few medicines, such as remdesivir, ribavirin, and favipiravir, are prescribed for the therapy, it is difficult to employ them specifically for the treatment of COVID-19 infection due to a lack of clinical data. These medicines were discovered to have a high affinity for the COVID-19 primary protease. Antimalarial medications like chloroquine and hydroxychloroquine, on the other hand, had a strong binding affinity with the SARS spike glycoprotein and the ACE2 complex. Vaccination has begun in India, although clinical data on safety and efficacy will not be available for some time. Even after immunization, everyone should be upbeat and follow the instructions to the letter. It's also been noted that we're dealing with not only COVID-19 but also its fear, particularly in India. Coronavirus Susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update Deconvoluting hepatic processing of carbon nanotubes Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Critical care management of adults with community-acquired severe respiratory viral infection What is the role of supplementation with ascorbic acid, zinc, vitamin D, or Nacetylcysteine for prevention or treatment of COVID-19? The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions Advances in respiratory virus therapeutics -a meeting report from the 6th isirv antiviral group conference Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains Deployment of convalescent plasma for the prevention and treatment of COVID-19 Joint HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Anticoagulant treatment in COVID-19: a narrative review Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy Virology, transmission, and pathogenesis of SARS-CoV-2 The effect of early treatment with Ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled Inhalation of nitric oxide in the treatment of severely acute respiratory syndrome: a rescue trial in Beijing Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan. China: a descriptive study Salvage therapies for refractory hypoxemia in ARDS Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes Bamlanivimab (LY-Cov555) for the Treatment of Covid-19 Accessed 04 Carbon nanotube as a tool for fighting cancer Approved Vaccines Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod The GReek study in the Effects of Colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design Novel Coronavirus-Important Information for Clinicians Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study Clinical characteristics of fatal and recovered cases of coronavirus disease China: a retrospective study Discovering drugs to treat coronavirus disease 2019 (COVID-19) A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV) What is 2-deoxy-D-glucose(2-DG) and is it effective against Covid?economictimes.indiatimes Web Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Baricitinib for COVID-19: a suitable treatment Influenza A virus mimetic nanoparticles trigger selective cell uptake Immunemediated approaches against COVID-19 Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase COVID-19 in kidney transplant recipients A review on the effect of COVID-19 in type 2 asthma and its management COVID-19: drug targets and potential treatments Novel corona virus (COVID-19). Global efforts and effective investigational medicines: a review Rapid COVID-19 vaccine development Guidelines on the management of acute respiratory distress syndrome Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor Branched polymer-drug conjugates for multivalent blockade of angiotensin II receptors Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Anakinra for severe forms of COVID-19: a cohort study Graphene quantum dotsbased systems as HIV inhibitors Covid-19: SaNOtize files for emergency approval in UK, Canada for its nasal spray treatment FDA resumes eIND approval for severeto-criticalCOVID-19 patients use of Vyrologix™ (leronlimab) following full enrollment in CytoDyn's Phase 3 Trial. Globenewswire Web Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients Enhanced dermal delivery of acyclovir using solid lipid nanoparticles Effect of COVID-19 on the Organs Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2 Current understanding of novel coronavirus: molecular pathogenesis, diagnosis, and treatment approaches 0 2 0 ) Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: an evidence-based clinical practice guideline (updated version) Mode of antiviral action of silver nanoparticles against HIV-1 Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Clinical observation and management of COVID-19 patients Coronavirus disease (COVID-19): role of chest CT in diagnosis and management. Cardiovasc Imaging Coronavirus vaccine development: from SARS and MERS to COVID-19 Umifenovir treatment is not associated with improved outcomes in patients with Corona-virus disease 2019: a retrospective study Clinical outcomes and plasma concentrations of baloxavirmarboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial Drug treatment options for the 2019-new coronavirus (2019-nCoV) Tocilizumab treatment in COVID-19: a single center experience Single-walled carbon nanotube (SWCNT)-induced interstitial fibrosis in the lungs of rats is associated with increased levels of PDGF mRNA and the formation of unique intercellular carbon structures that bridge alveolar macrophages in situ Antiviral activities of type I interferons to SARS-CoV-2 infection Danoprevir: first global approval Monoclonal antibodies for prevention and treatment of COVID-19 Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus Nanoparticle-based strategies to combat COVID-19 Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome (ARDS)? The improbability of the rapid development of a vaccine for SARS-CoV-2 Monoclonal antibodies to disrupt progression of early Covid-19 infection CNS implications of COVID-19: a comprehensive review National Health Commission and State Administration of Traditional Chinese Medicine (2020) Diagnosis and treatment protocol for novel coronavirus pneumonia Development of Diagnostic Tests for Detection of SARS-CoV-2 Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to COVID-19: current understanding of its pathophysiology, clinical presentation and treatment Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches? COVID-19 treatment by repurposing drugs until the vaccine is in sight Emergent inpatient administration of Casirivimab and Imdevimab antibody cocktail for the treatment of COVID-19 pneumonia Quinacrine as a potential treatment for COVID-19 virus infection Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutic in COVID-19 Metal nanoparticles: the protective nanoshield against virus infection Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial COVID-19 vaccine tracker. RAPS Web Anti-inflammatory therapy for COVID-19 infection: the case for colchicines Environ Sci Pollut Res treatment for 2019-nCoV acute respiratory disease Convalescent plasma in Covid-19: possible mechanisms of action Clinical trials on drug repositioning for COVID-19 treatment Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan China Clinical evidence does not support corticosteroid treatment for 2019-CoV lung injury Immune-modifying and antimicrobial effects of eucalyptus oil and simple inhalation devices Tocilizumab in patients hospitalized with Covid-19 pneumonia Type 1 interferons as a potential treatment against COVID-19 Pharmacologic treatments for coronavirus diseases 2019 (COVID-19): a review Drug targets for COVID-19 therapeutics: Ongoing global efforts Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology DCGI approves virafin for moderate COVID. where's the evidence it works Lipid-Based Nanocarriers for Drug Delivery and Diagnosis A review on the contemporary status of mutating coronavirus and comparative literature study of current COVID-19 vaccines A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world A journey from SARS-CoV-2 to COVID-19 and beyond: a comprehensive insight of epidemiology, diagnosis, pathogenesis, and overview of the progress into its therapeutic management Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis Essential oils as antiviral agents. Potential of essential oils to treat SARS-CoV-2 infection: an in-silico investigation Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles The role of nanotechnology in the treatment of viral infections. The role of nanotechnology in the treatment of viral infections Efficacy and safety of new and emerging drugs for COVID-19: Favipiravir and Dexamethasone Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. VOX Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1)pdm09 virus infection by interfering with virus internalization process Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro A mini review on carbon quantum dots: preparation, properties, and electrocatalytic application Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia Magnetic nanoparticles for targeted cancer diagnosis and therapy. Front Nanosci Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide Broad spectrum antiviral agent niclosamide and its therapeutic potential COVID-19 vaccines: a review of the safety and efficacy of current clinical trials Clinical characteristics and outcomes of coronavirus disease 2019 patients who received compassionate-use leronlimab Application of Nanotechnology in the COVID-19 Pandemic The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China A pneumonia outbreak associated with a new coronavirus of probable bat origin COVID-19 Update: NACI weighs in on "preferred" vaccines; mixing doses is possibility Potently neutralizing and protective human antibodies against SARS-CoV-2 Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Acknowledgements The authors acknowledge the Management of Devsthali Vidyapeeth College of Pharmacy for providing continuous support for the article.Author Contribution Conceptualization V.T. and A.T.; writing-original draft preparation M.K. and B.M.S.; writing-review and editing S.S., S.K., and R.S. All authors have read and approved the manuscript.Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.Data Availability Available on request. Ethics approval and consent to participate Not applicable. Competing interests The authors declare no competing interests.